PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Trevigen, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Cultrex® Mouse Laminin I Now Qualified 'PathClear®' - Trevigen adds mouse Laminin I to PathClear® designated products for research Involving cancer cell characterization and behavior
Cultrex® Mouse Laminin I Now Qualified 'PathClear®'

 

NewswireToday - /newswire/ - Arlington, VA, United States, 2008/08/20 - Trevigen adds mouse Laminin I to PathClear® designated products for research Involving cancer cell characterization and behavior.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cancer researchers are finding more uses for mouse laminin I derived from EHS Sarcoma. Cancer cell characterization and modulation of behavior in response to putative attractants or inhibitors underlie important aspects of cancer research. Cell adhesion, migration, growth and differentiation are all studied using mouse laminin I along with other specialized proteins available from Trevigen, Inc.

Proteins derived from the EHS sarcoma have been found to harbor murine viruses such as LDEV, which may not be detected by MAP testing. The presence of these viruses could affect experimental results and cause incorrect conclusions. The reason that viruses may be present but not detected is that traditional manufacturing approaches do not remove all pathogens. Viruses may be present in low enough concentrations to be beneath the threshold of detection for the standard MAP Assays.

To solve these problems Trevigen has developed a new (patent applied for) manufacturing process which preserves both the biochemical integrity and the biological performance of mouse laminin I while eliminating the problem of low concentration viruses. In addition to the standard sterility, mycoplasma, endotoxin and MAP tests, the mouse laminin I is tested by PCR and cleared of a battery of 31 mouse pathogens including LDEV. This eliminates concern that contaminating agents may interfere and cause erroneous test results. Mouse laminin I produced by the new process is rigorously tested for contaminating organisms and designated PathClear®.

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.

PathClear® BME, Mouse laminin I antibody, and other specialty proteins are also available separately from Trevigen.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Trevigen, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cultrex® Mouse Laminin I Now Qualified 'PathClear®'

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

PathClear® Laminin |
Publisher Contact: Belinda De Leon - Trevigen.com 
1.800.873.8443 info[.]trevigen.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Trevigen, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Trevigen, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)